The L-arginine/nitric oxide pathway contributes to the acute release of tissue plasminogen activator in vivo in man

Cardiovascular Research

Volumn 38, Issue 2, 1998, Pages 485-492

  Newby, David E ^a   Wright, Robert A ^a   Dawson, Pamela ^a   Ludlam, Christopher A ^a   Boon, Nicholas A ^a   Fox, Keith A A ^a   Webb, David J ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Blood flow; Endothelial factor; Endothelial function; Nitric oxide; Thrombolysis

Indexed keywords

ARGININE; FIBRINOLYTIC FACTOR; HEMOSTATIC AGENT; N(G) METHYLARGININE; NITRIC OXIDE; PLASMINOGEN ACTIVATOR INHIBITOR 1; SUBSTANCE P; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; BLOOD FLOW; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FIBRINOLYSIS; HUMAN; HUMAN EXPERIMENT; IN VIVO STUDY; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANALYSIS OF VARIANCE; AREA UNDER CURVE; DOSE-RESPONSE RELATIONSHIP, DRUG; FOREARM; HUMANS; MALE; NITRIC OXIDE SYNTHASE; OMEGA-N-METHYLARGININE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLETHYSMOGRAPHY; REGIONAL BLOOD FLOW; SUBSTANCE P; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0003916967     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(98)00017-0     Document Type: Article

References (45)

1. [1] DeWood MA, Spores J, Notske R, et al. Prevalence of total coronary artery occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980;303:897-902.
2. [2] Rentrop KP, Feit F, Blanke H, Sherman W, Thornton JC. Serial angiographic assessment of coronary artery obstruction and collateral flow in acute myocardial infarction. Circulation 1989;80:1166-1175.
3. [3] Armstrong PW, Baigrie RS, Daly PA, et al. Tissue plasminogen activator: Toronto (TPAT) placebo-controlled randomised trial in acute myocardial infarction. J Am Coll Cardiol 1989;13:1469-1476.
4. [4] Fox KAA, Robison AK, Knabb RM, et al. Prevention of coronary thrombosis with subthrombolytic doses of tissue-type plasminogen activator. Circulation 1984;72:1346-1354.
5. [5] Brommer EJP. The level of extrinsic plasminogen activator (t-PA) during clotting as a determinant of the rate of fibrinolysis; inefficiency of activators added afterwards. Thromb Res 1984;34:109-115.
6. [6] Hamsten A, Wiman B, de Faire U, Blombäck M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985;313:1557-1563.
7. [7] Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Hennekens CH. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 1993;341:1165-1168.
8. [8] Ridker PM, Hennekens CH, Stampfer MJ, Manson JE, Vaughan DE. Prospective study of endogenous tissue plasminogen activator and risk of stroke. Lancet 1994;343:940-943.
9. [9] Thompson SG, Kienast J, Pyke SDM, Haverkate F, van de Loo JCW. For the European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995;332:635-641.
10. [10] Jern C, Ladenwall P, Wall U, Jern S. Gene polymorphism associated with vascular release of tissue-type plasminogen activator (t-PA) in vivo. Eur Heart J 1997;18:144. Abstract.
11. [11] Newby DE, Wright RA, Ludlam CA, et al. An in vivo model for the assessment of the acute fibrinolytic capacity of the endothelium. Thromb Haemost 1997;78:1242-1248.
12. [12] Ludlam CA, Peake IR, Allen N, et al. Factor VIII and fibrinolytic response to deamino-8-D-arginine vasopressin in normal subjects and dissociate response in some patients with haemophilia and von Willebrand's disease. Br J Haematol 1980;45:499-511.
13. [13] Tranquille N, Emeis JJ. The involvement of products of the phospholipase pathway in the acute release of tissue-type plasminogen activator from perfused rat hindlegs. Eur J Pharmacol 1992;213:285-292.
14. [14] Ridker PM, Gaboury CL, Conlin PR, et al. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Circulation 1993;87:1969-1973.
15. [15] Gross DR, Fiscus RR, Arden WA, et al. Substance P induces biphasic endothelium-dependent relaxations in pig and rabbit carotid arteries. Neuropeptides 1994;26:329-341.
16. [16] Stjärne P, Rinder J, Delay-Goyet P. Effects of NK1 receptor antagonists on vasodilation induced by chemical and electrical activation of sensory C-fibre afferents in different organs. Acta Physiol Scand 1994;152:153-161.
17. G-monomethyl-L-arginine on kinin-induced vasodilation in the human forearm. Br J Clin Pharmacol 1994;38:307-310.
18. [18] Newby DE, Boon NA, Webb DJ. Comparison of forearm vasodilatation induced by substance P and acetylcholine: contribution of nitric oxide. Clin Sci 1997;92:133-138.
19. [19] Quyyumi AA, Mulcahy D, Andrews NP, et al. Coronary vascular nitric oxide activity in hypertension and hypercholesterolemia. Circulation 1997;95:104-110.
20. [20] Jern S, Selin L, Bergbrant A, Jern C. Release of tissue-type plasminogen activator in response to muscarinic receptor stimulation in human forearm. Thromb Haemost 1994;72:588-594.
21. [21] Benjamin N, Calver A, Collier J, et al. Measuring forearm blood flow and interpreting the responses to drugs and mediators. Hypertension 1995;25:918-923.
22. [22] Wiinberg N, Walter-Larson S, Eriksen C, Nielsen PE. An evaluation of semi-automatic blood pressure manometers against intra-arterial blood pressure. J Ambul Monitor 1988;1:303-309.
23. [23] Plumpton C, Haynes WG, Webb DJ, Davenport AP. Phosphoramidon inhibition of the in vivo conversion of big endothelin-1 to endothelin-1 in the human forearm. Br J Pharmacol 1995;116:1821-1828.
24. [24] Declerck PJ, Alessi MC, Verstreken M, et al. Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. Blood 1988;71:220-225.
25. [25] Booth NA, Walker E, Maughan R, Bennett B. Plasminogen activator in normal subjects after exercise and venous occlusion: t-PA circulates as complexes with C1-inhibitor and PAI-1. Blood 1987;69:1600-1604.
26. [26] Wiman B, Lindahl T, Almqvist. Evidence for a discrete binding protein of plasminogen activator inhibitor in plasma. Thromb Haemost 1988;59:392-395.
27. [27] Gram J, Kluft C, Jespersen J. Depression of tissue plasminogen activator (t-PA) activity and rise of t-PA inhibition and acute phase reactants in blood of patients with acute myocardial infarction (AMI). Thromb Haemost 1987;58:817-821.
28. [28] Cejka J. Enzyme immunoassay for factor VIII-related antigen. Clin Chem 1982;28:1356-1358.
29. [29] Tranquille N, Emeis JJ. On the role of calcium in the acute release of tissue-type plasminogen activator and von Willebrand factor from the rat perfused hindleg region. Thromb Haemost 1991;66:479-483.
30. [30] Rydholm H, Bostrom S, Eriksson E, Risberg B. Complex intracellular signal transduction regulates tissue plasminogen activator (t-PA) and plasminogen activator inhibitor type-1 (PAI-1) synthesis in cultured human umbilical endothelium. Scand J Clin Lab Invest 1995;55:323-330.
31. [31] Levin EG, Marzec V, Anderson J, Harker LA. Thrombin stimulates tissue plasminogen activator release from cultured endothelial cells. J Clin Invest 1984;74:1988-1995.
32. [32] Casonato A, Sartori MT, Pontara E. Impaired release of tissue plasminogen activator (t-PA) following DDAVP infusion in von Willebrand's disease with low platelet von Willebrand factor. Blood Coagul Fibrinolysis 1992;3:149-153.
33. [33] Panza JA, Casino PR, Kilcoyne CM, Quyyumi AA. Impaired endothelium-dependent vasodilation in patients with essential hypertension: evidence that the abnormality is not at the muscarinic receptor level. J Am Coll Cardiol 1994;23:1610-1616.
34. [34] Casino PR, Kilcoyne CM, Cannon RO, et al. Impaired endothelium-dependent vascular relaxation in patients with hypercholesterolaemia extends beyond the muscarinic receptor. Am J Cardiol 1995;75:40-44.
35. [35] Stroes ES, Koomans HA, de Bruin TWA, Rabelink TJ. Vascular function in the forearm of hypercholesterolaemic patients off and on lipid-lowering medication. Lancet 1995;346:467-471.
36. [36] Celermajer DS, Adams MR, Clarkson P, et al. Passive smoking and impaired endothelium-dependent arterial dilatation in healthy young adults. N Engl J Med 1996;334:150-154.
37. [37] McEwan JR, Benjamin N, Larkin S, et al. Vasodilatation by calcitonin gene-related peptide and substance P: a comparison of their effects on resistance and capacitance vessels of human forearms. Circulation 1988;77:1072-1080.
38. [38] Bowden JJ, Garland AM, Baluk P, et al. Direct observation of substance P-induced internalisation of neurokinin 1 (NK1) receptors at sites of inflammation. Proc Natl Acad Sci USA 1994;91:8964-8968.
39. [39] Kuroiwa M, Aoki H, Kobayashi S, et al. Mechanism of endothelium-dependent relaxation induced by substance P in the coronary artery of the pig. Br J Pharmacol 1995;116:2040-2047.
40. [40] Chandler WL, Alessi MC, Aillaud MF, et al. Clearance of tissue plasminogen activator (TPA) and TPA/plasminogen activator inhibitor type 1 (PAI-1) complex. Circulation 1997;96:761-768.
41. [41] Lucore CL, Sobel BE. Interactions of tissue-type plasminogen activator with plasma inhibitors and their pharmacological implications. Circulation 1988;77:660-669.
42. [42] Otter M, Kuiper J, van Berkel JC, Rijken DC. Mechanisms of tissue-type plasminogen activator (tPA) clearance by the liver. Ann NY Acad Sci 1992;667:431-442.
43. [43] Andreotti F, Kluft C. Circadian variation of fibrinolytic activity in blood. Chronobiol Int 1991;8:336-351.
44. [44] Jern C, Selin L, Jern S. In vivo release of tissue-type plasminogen activator across the human forearm during mental stress. Thromb Haemost 1994;72:285-291.
45. [45] Jern C, Selin L, Tengborn L, Jern S. Sympathoadrenal activation and muscarinic receptor stimulation stimulate acute release of tissue-type plasminogen activator but not von Willebrand factor across the human forearm. Thromb Haemost 1997;78:887-891.